SEZI — Senzime AB (publ) Share News
0.000.00%
- SEK551.04m
- SEK543.27m
- SEK104.02m
Brief: Senzime Resolves On Rights Issue Of About SEK 100 Mln
Brief: Senzime Preliminary Q4 Sales Rise To SEK 4.6 Mln
Brief: Senzime Receives Contract For Tetrasens Pediatric In U.S.
Brief: Senzime Estimates Net Sales To Reach SEK 275 Mln - 325 Mln By 2025
Brief: Senzime Q3 EBITDA Loss Widens To SEK 24.7 Mln
Brief: Senzime Says ASA Approves Guidelines For Neuromuscular Blockade Monitoring
Brief: Senzime: New Study Confirms Effectiveness Of Tetragraph
Brief: Senzimes Receives FDA 510k-Clearance For New Disposable Sensor
Brief: Senzime Q2 Loss After Financial Items Widens To SEK 40.9 Mln
Brief: Senzime Signs Strategic License And Connectivity Agreement
Brief: Senzime Enters Into Agreement To Buy U.S. Company Respiratory Motion
Brief: Senzime Completes Directed Share Issue
Brief: Senzime Q1 Loss After Financial Items SEK 21.0 Mln
Brief: Senzime Gets CE-MDR Approval For Disposable Sensor For Small Children
Brief: Senzime Gets US Order With An Initial Value Exceeding SEK 1 Mln
Brief: Senzime Wins US Deal For 23 Tetragraph Systems
Brief: Senzime Applies For FDA Approval For New Single-Use Sensor For Children
Brief: Senzime Signs Deal For 50 Tetragraph Systems Worth About SEK 1.5 Mln Per Year
Brief: Senzime Q4 Loss After Financial Items Widens To SEK 24.4 Mln